Amgen To Pay $95M In Class Action Securities Settlement
Global biotechnology company Amgen Inc. has reached a $95 million settlement with investors over alleged misstatements about two of its anti-anemia drugs, according to settlement documents filed in California federal court...To view the full article, register now.
Already a subscriber? Click here to view full article